Drug Diversion Monitoring 2021
Are the Next-Gen Tools Ready for Prime Time?

Author
Jackson Tate

Author
Paul Warburton

March 18, 2021 | Read Time: 4 minutes

Static for some time, the drug diversion monitoring market has seen a recent wave of next-generation solutions that seek to streamline the investigation process by providing consolidated, prioritized insights and more proactive alerting. However, these solutions are not all created equal. This report examines the customer experience of four next-gen vendors that have achieved broader integration and adoption—FairWarning, HelioMetrics, Invistics, and Kit Check. It also provides early insights on several next-gen solutions that are in more developmental phases (BD, Medacist, and Protenus). KLAS interviewed approximately 50% of the organizations that were live with a next-gen solution at the time this research was collected.

to see the full dataset.

if you don't have a login, getting started is easy.

Provider Organizations

Fill out our registration form to verify your organization.

HIT Companies

Contact a KLAS representative for plans and pricing.

Key Findings:

Kit Check Emerging as Most Mature Option in New Batch of Next-Gen Solutions
Kit Check and FairWarning Best at Meeting Customers’ Expectations for Diversion Monitoring 2.0
Vendor Performance in Key Metrics

Writer
Elizabeth Pew

Project Manager
Natalie Jamison

Download Report Brief Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2022 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.